Nedeni Açıklanamayan İnfertilite
Özet
Nedeni açıklanamayan infertilite, standart testlerde (ovulatuar fonksiyon, tubal açıklık ve semen analizi) herhangi bir sorun saptanamaması durumunda konulan bir dışlama tanısıdır. Görülme sıklığı %10-30 arasında değişmekte olup, kadın yaşının ilerlemesi (özellikle 35 yaş sonrası) tanı koymayı zorlaştırmaktadır. Nedeni bilinmediği için tedaviler ampirik olarak uygulanır. Bekleme yönetimi; evlilik süresi kısa, genç ve iyi prognozlu çiftlerde makul gebelik oranları sağlayan bir seçenek olarak değerlendirilebilir. Ancak iki yıl veya daha uzun süreli infertilitede ya da 35 yaş üstü kadınlarda daha agresif tedaviler gerekir. Kanıtlara göre doğal siklustaki IUI veya sadece klomifen sitrat ile letrozol gibi oral ajanların kullanımı, bekleme yönetimine kıyasla ek bir fayda sağlamamaktadır. Buna karşın, oral ajanlar veya gonadotropinler ile ovaryan stimulasyonun IUI ile kombine edilmesi (özellikle gonadotropin/IUI) gebelik oranlarını anlamlı ölçüde artırır; ancak gonadotropin kullanımı daha yüksek çoğul gebelik riski taşır. Yardımcı üreme teknikleri (IVF-ICSI) ise en etkili tedavi yöntemi olup, özellikle 38 yaş üstü kadınlarda IUI'a kıyasla belirgin şekilde yüksek canlı doğum oranı sunar. 38 yaşından küçük çiftlerde ise daha az invaziv ve maliyet etkin olan IUI birinci basamak tedavi olarak tercih edilebilir. Sonuç olarak tedavi seçimi; çiftin yaşı, over rezervi, maliyetler, riskler ve yasal mevzuatlar dikkate alınarak ortak kararla belirlenmelidir.
Unexplained infertility is a diagnosis of exclusion considered when standard assessments of ovulatory function, tubal patency, and semen analysis show no abnormalities, affecting an estimated 10% to 30% of infertile couples. Distinguishing unexplained infertility becomes increasingly difficult as female age advances, particularly after age 35, which strongly dictates live birth rates. Since the underlying cause remains unknown, management strategies are empirical, historically progressing from less invasive approaches to assisted reproductive technologies. Expectant management serves as a viable option for younger couples with a short duration of infertility and favorable prognosis, yielding reasonable pregnancy rates, whereas couples infertile for over two years or with a female partner older than 35 require more aggressive interventions. Current evidence indicates that intrauterine insemination (IUI) in natural cycles or ovarian stimulation using only oral agents like clomiphene citrate or letrozole provides no additional benefit over expectant management. Conversely, combining oral agents or gonadotropins with IUI significantly enhances cycle fecundity compared to no treatment, although gonadotropin/IUI cycles are associated with a higher risk of multiple pregnancies. Ultimately, in vitro fertilization (IVF-ICSI) stands as the most effective first-line treatment per cycle, demonstrating statistically significant higher live birth rates for women over 38, while ovarian stimulation combined with IUI remains a suitable, less invasive, and cost-effective first-line alternative for couples under the age of 38.
Referanslar
Crosignani PG, Collins J, Cooke ID,et al. The recommendations of the ESHRE workshop on ‘Unexplained Infertility’. Anacapri, August 28–29, 1992. Hum Reprod;8(6):977–80.
Stewart JD, Pasternak MC, Pereira N, et al. Contemporary Management of Unexplained Infertility. Clin Obstet Gynecol. 2019;62(2):282–92.
Buckett W, Sierra S. The management of unexplained infertility: an evidence-based guideline from the Canadian Fertility and Andrology Society. Reprod Biomed Online. 2019;39(4):633–40.
Somigliana E, Paffoni A, Busnelli A, et al. Age-related infertility and unexplained infertility: an intricate clinical dilemma. Hum Reprod. 2016;31(7):1390–6.
Hatasaka H. New perspectives for unexplained infertility. Clin Obstet Gynecol. 2011;54(4):727–33.
Hull MG, Glazener CM, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. Br Med J. 1985;291(6510):1693–7.
Eijkemans MJC, Lintsen AME, Hunault CC, et al. Pregnancy chances on an IVF/ICSI waiting list: a national prospective cohort study. Hum Reprod. 2008;23(7):1627–32.
Steures P, van der Steeg JW, Hompes PGA, et al. Intrauterine insemination with controlled ovarian hyperstimulation versus expectant management for couples with unexplained subfertility and an intermediate prognosis: a randomised clinical trial. Lancet. 2006;368(9531):216–21.
Bhattacharya S, Harrild K, Mollison J, et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ. 2008;337:a716.
Veltman-Verhulst SM, Hughes E, Ayeleke RO, et al. Intra-uterine insemination for unexplained subfertility. Cochrane database Syst Rev. 2016;2:CD001838.
Wang R, Danhof NA, Tjon-Kon-Fat RI, et al. Interventions for unexplained infertility: a systematic review and network meta-analysis. Cochrane database Syst Rev. 2019;9(9):CD012692.
Ayeleke RO, Asseler JD, Cohlen BJ, et al. Intra-uterine insemination for unexplained subfertility. Cochrane database Syst Rev. 2020;3:CD001838.
Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. N Engl J Med. 1999;340(3):177–83.
Hughes E, Brown J, Collins JJ, et al. Clomiphene citrate for unexplained subfertility in women. Cochrane database Syst Rev. 2010;2010(1):CD000057.
Liu A, Zheng C, Lang J, et al. Letrozole versus clomiphene citrate for unexplained infertility: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2014;40(5):1205–16.
Gleicher N, Oleske DM, Tur-Kaspa I, et al. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med. 2000;343(1):2–7.
Guzick DS, Sullivan MW, Adamson GD, et al. Efficacy of treatment for unexplained infertility. Fertil Steril. 1998;70(2):207–13.
Deaton JL, Gibson M, Blackmer KM, et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril. 1990;54(6):1083–8.
Farquhar CM, Liu E, Armstrong S, et al. Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial. Lancet.2018;391(10119):441–50.
Fouda UM, Sayed AM. Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:84.
Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med. 2015;373(13):1230–40.
Berker B, Kahraman K, Taskin S, et al. Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial. Arch Gynecol Obstet. 2011;284(6):1561–6.
Dankert T, Kremer JAM, Cohlen BJ, et al. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Hum Reprod. 2007;22(3):792–7.
NICE (National Institute for Clinical Excellence) Fertility. 2013 Assessment and treatment for people with fertility problems. https://www.nice.org.uk/guidance/cg156 (Accesssed 7th February 2022).
Cantineau AE, Rutten AG, Cohlen BJ. Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility. Cochrane database Syst Rev. 2021;11(11):CD005356.
Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PMM, et al. Prevention of multiple pregnancies in couples with unexplained or mild male subfertility: randomised controlled trial of in vitro fertilisation with single embryo transfer or in vitro fertilisation in modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation. BMJ. 2015;350:g7771.
Custers IM, König TE, Broekmans FJ, et al. Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation. Fertil Steril. 2011;96(5):1107-11.e1.
Nandi A, Bhide P, Hooper R, et al. Intrauterine insemination with gonadotropin stimulation or in vitro fertilization for the treatment of unexplained subfertility: a randomized controlled trial. Fertil Steril. 2017;107(6):1329-1335.e2.
Pandian Z, Gibreel A, Bhattacharya S. In vitro fertilisation for unexplained subfertility. Cochrane database Syst Rev. 2015;2015(11):CD003357.
Nandi A, Raja G, White D, et al. Intrauterine insemination + controlled ovarian hyperstimulation versus in vitro fertilisation in unexplained infertility: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021; doi: 10.1007/s00404-021-06277-3. Epub ahead of print
Tjon-Kon-Fat RI, Tajik P, Zafarmand MH, et al. IVF or IUI as first-line treatment in unexplained subfertility: the conundrum of treatment selection markers. Hum Reprod. 2017;32(5):1028–32.
